<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MDM</journal-id>
<journal-id journal-id-type="hwp">spmdm</journal-id>
<journal-id journal-id-type="nlm-ta">Med Decis Making</journal-id>
<journal-title>Medical Decision Making</journal-title>
<issn pub-type="ppub">0272-989X</issn>
<issn pub-type="epub">1552-681X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0272989X10397615</article-id>
<article-id pub-id-type="publisher-id">10.1177_0272989X10397615</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles: Health-Related Quality of Life</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Effect of Treatment Interruption and Intensification of Antiretroviral Therapy on Health-Related Quality of Life in Patients with Advanced HIV</article-title>
<subtitle>A Randomized, Controlled Trial</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Joyce</surname><given-names>Vilija R.</given-names></name>
<degrees>MS</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Barnett</surname><given-names>Paul G.</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Chow</surname><given-names>Adam</given-names></name>
<degrees>BA</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Bayoumi</surname><given-names>Ahmed M.</given-names></name>
<degrees>MD, MSc</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Griffin</surname><given-names>Susan C.</given-names></name>
<degrees>MSc</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Sun</surname><given-names>Huiying</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Holodniy</surname><given-names>Mark</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Brown</surname><given-names>Sheldon T.</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Kyriakides</surname><given-names>Tassos C.</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Cameron</surname><given-names>D. William</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Youle</surname><given-names>Mike</given-names></name>
<degrees>MB, ChB</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Sculpher</surname><given-names>Mark</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Anis</surname><given-names>Aslam H.</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Owens</surname><given-names>Douglas K.</given-names></name>
<degrees>MD, MS</degrees>
</contrib>
</contrib-group>
<aff id="aff1-0272989X10397615">VA Palo Alto Health Care System, VA Cooperative Studies Program Coordinating Center, VA HSR&amp;D Health Economics Resource Center, Menlo Park, California (VRJ, PGB, AC)</aff>
<aff id="aff2-0272989X10397615">Centre for Research on Inner City Health, The Keenan Research Centre in the Li Ka Shing Knowledge Institute and Division of General Internal Medicine, St. Michael’s Hospital, Toronto, Ontario, Canada and Departments of Medicine and Health Policy, Management and Evaluation, University of Toronto, Ontario, Canada (AMB)</aff>
<aff id="aff3-0272989X10397615">Centre for Health Economics, University of York, York, United Kingdom (SCG, MS)</aff>
<aff id="aff4-0272989X10397615">Centre for Health Evaluation and Outcome Sciences, St. Paul’s Hospital, Vancouver, British Columbia, Canada (HS)</aff>
<aff id="aff5-0272989X10397615">Canadian HIV Trials Network, Vancouver, British Columbia, Canada (HS, AHA)</aff>
<aff id="aff6-0272989X10397615">VA Palo Alto Health Care System, Palo Alto, California (MH, DKO)</aff>
<aff id="aff7-0272989X10397615">James J. Peters VA Medical Center, Bronx, New York (STB)</aff>
<aff id="aff8-0272989X10397615">VA Cooperative Studies Program Coordinating Center, West Haven, Connecticut (TCK)</aff>
<aff id="aff9-0272989X10397615">Division of Infectious Diseases, University of Ottawa at the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada (DWC)</aff>
<aff id="aff10-0272989X10397615">Royal Free Hospital, London, United Kingdom (MY)</aff>
<aff id="aff11-0272989X10397615">Department of Health Care and Epidemiology, University of British Columbia, Vancouver, British Columbia, Canada (AHA)</aff>
<aff id="aff12-0272989X10397615">Center for Primary Care and Outcomes Research, Stanford University, Stanford, California (DKO)</aff>
<author-notes>
<corresp id="corresp1-0272989X10397615">Vilija R. Joyce, MS, Health Economics Resource Center (HERC), VA Palo Alto Health Care System, 795 Willow Road (152 MPD), Menlo Park, CA 94025; telephone: (650) 493-5000 ext. 23852; fax: (650) 617-2639; e-mail: <email>vilija.joyce@va.gov</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>32</volume>
<issue>1</issue>
<fpage>70</fpage>
<lpage>82</lpage>
<history>
<date date-type="received">
<day>14</day>
<month>7</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>8</day>
<month>12</month>
<year>2010</year>
</date>
</history>
<abstract>
<p><bold>Background</bold>. The effect of antiretroviral therapy (ART) interruption or intensification on health-related quality of life (HRQoL) in advanced HIV patients is unknown. <bold>Objective</bold>. To assess the impact of temporary treatment interruption and intensification of ART on HRQoL. <bold>Design</bold>. A 2 x 2 factorial open label randomized controlled trial. <bold>Setting</bold>. Hospitals in the United States, Canada, and the United Kingdom. <bold>Patients</bold>. Multidrug resistant (MDR) HIV patients. <bold>Intervention</bold>. Patients were randomized to receive a 12-wk interruption or not, and ART intensification or standard ART. <bold>Measurements</bold>. The Health Utilities Index (HUI3), EQ-5D, standard gamble (SG), time tradeoff (TTO), visual analog scale (VAS), and the Medical Outcomes Study HIV Health Survey (MOS-HIV). <bold>Results</bold>. There were no significant differences in HRQoL among the four groups during follow-up; however, there was a temporary significant decline in HRQoL on some measures within the interruption group during interruption (HUI3 −0.05, <italic>P</italic> = 0.03; VAS −5.9, <italic>P</italic> = 0.002; physical health summary −2.9, <italic>P</italic> = 0.001; mental health summary −1.9, <italic>P</italic> = 0.02). Scores declined slightly overall during follow-up. Multivariate analysis showed significantly lower HRQoL associated with some clinical events. <bold>Limitations</bold>. The results may not apply to HIV patients who have not experienced multiple treatment failures or who have not developed MDR HIV. <bold>Conclusions</bold>. Temporary ART interruption and ART intensification provided neither superior nor inferior HRQoL compared with no interruption and standard ART. Among surviving patients, HRQoL scores declined only slightly over years of follow-up in this advanced HIV cohort; however, approximately one-third of patients died during the trial follow up. Lower HRQoL was associated with adverse clinical events.</p>
</abstract>
<kwd-group>
<kwd>AIDS</kwd>
<kwd>HIV</kwd>
<kwd>highly active antiretroviral therapy</kwd>
<kwd>quality of life</kwd>
<kwd>treatment interruption</kwd>
<kwd>treatment intensification</kwd>
<kwd>randomized trial</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January–February 2012</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>Highly active antiretroviral therapy has significantly improved survival and morbidity in HIV-1–infected patients.<sup><xref ref-type="bibr" rid="bibr1-0272989X10397615">1</xref>–<xref ref-type="bibr" rid="bibr3-0272989X10397615">3</xref></sup> However, treatment-experienced patients often experience incomplete suppression of viremia due to difficulties with adherence<sup><xref ref-type="bibr" rid="bibr4-0272989X10397615">4</xref></sup> and the emergence of multidrug-resistant (MDR) HIV-1,<sup><xref ref-type="bibr" rid="bibr5-0272989X10397615">5</xref>–<xref ref-type="bibr" rid="bibr7-0272989X10397615">7</xref></sup> which lead to a corresponding increase in AIDS-defining events and death.<sup><xref ref-type="bibr" rid="bibr8-0272989X10397615">8</xref></sup> In addition, antiretroviral therapy (ART) may cause significant toxicity and side effects, particularly for patients who have failed first- and second-line therapies.</p>
<p>There is no consensus on the optimal management strategy for patients infected with MDR HIV-1 when fully suppressive regimens have been exhausted or are unavailable.<sup><xref ref-type="bibr" rid="bibr9-0272989X10397615">9</xref></sup> Continuation of a nonsuppressive ART regimen may lead to additional drug resistance<sup><xref ref-type="bibr" rid="bibr10-0272989X10397615">10</xref>,<xref ref-type="bibr" rid="bibr11-0272989X10397615">11</xref></sup> while exposing patients to unnecessary drug-related toxicities. Intensifying antiretroviral therapy, with at least 5 and up to 9 drugs, is another strategy for viral suppression in heavily pretreated patients; however, concerns about tolerability and long-term multiple drug-related toxicities remain.<sup><xref ref-type="bibr" rid="bibr12-0272989X10397615">12</xref>–<xref ref-type="bibr" rid="bibr14-0272989X10397615">14</xref></sup></p>
<p>The Options in Management with Antiretrovirals (OPTIMA) study was a 3-nation trial that randomized MDR HIV-1–infected patients to an intended 12-wk treatment interruption or no interruption and to ART intensification (5 or more antiretroviral drugs) or standard ART (4 or fewer antiretroviral drugs).<sup><xref ref-type="bibr" rid="bibr15-0272989X10397615">15</xref></sup> The trial found no significant differences for the primary outcome (time to first AIDS-defining event or death) or in the secondary outcome of time to first serious adverse event among the management strategy groups.<sup><xref ref-type="bibr" rid="bibr16-0272989X10397615">16</xref></sup></p>
<p>Health-related quality of life (HRQoL) can be assessed with descriptive HRQoL instruments that measure symptom severity or with preference- or utility-based instruments that assess the strength of a preference for an outcome and provide utilities essential for cost-effectiveness analyses.<sup><xref ref-type="bibr" rid="bibr17-0272989X10397615">17</xref>,<xref ref-type="bibr" rid="bibr18-0272989X10397615">18</xref></sup> Previous studies have assessed the impact of treatment interruptions on HRQoL,<sup><xref ref-type="bibr" rid="bibr19-0272989X10397615">19</xref>–<xref ref-type="bibr" rid="bibr29-0272989X10397615">29</xref></sup> but the effect of ART interruption or intensification on preference-based HRQoL is unknown.</p>
<p>As part of the OPTIMA trial, we used descriptive and preference-based instruments to assess the longitudinal effect of treatment interruption and ART intensification therapies on HRQoL in an MDR HIV-1–infected patient population. We also examined the clinical and sociodemographic characteristics associated with HRQoL in this cohort. We previously described the assessments of HRQoL at baseline<sup><xref ref-type="bibr" rid="bibr30-0272989X10397615">30</xref></sup>; here, we describe the effect of treatment assignment and clinical and sociodemographic variables on quality of life over time.</p>
<sec id="section1-0272989X10397615" sec-type="methods">
<title>Methods</title>
<sec id="section2-0272989X10397615">
<title>Study Population</title>
<p>The design and main findings of the OPTIMA trial have been reported previously.<sup><xref ref-type="bibr" rid="bibr15-0272989X10397615">15</xref>,<xref ref-type="bibr" rid="bibr16-0272989X10397615">16</xref></sup> Briefly, between June 2001 and June 2006, 368 participants in Canada, the United Kingdom, and the United States (Veterans’ Affairs hospitals) were enrolled in OPTIMA, with follow-up concluding in December 2007. HIV-1–infected patients were eligible if they had evidence of serial treatment failure or antiretroviral resistance, were receiving ART therapy, had CD4 counts ≤300 cells/mm<sup>3</sup>, and had HIV-1 viral load levels ≥5000 copies/mL (Amplicor Monitor 1.0 or 1.5 assay; Roche, Basel, Switzerland) or ≥2500 copies/mL (Versant 3.0 branched DNA; Siemens, New York, NY).</p>
</sec>
<sec id="section3-0272989X10397615">
<title>Study Design</title>
<p>Participants were factorial randomized to a 12-wk treatment interruption or no interruption and to either intensification of ART (5 or more drugs) or standard ART (4 or fewer drugs). In the United Kingdom, the trial protocol was amended to allow patients to participate without being randomized for treatment interruption. The primary outcome was time to first new or recurrent AIDS-defining event or death, and the secondary endpoint was time to first serious adverse event. Other outcomes included HRQoL, the incidence of grade 3 or 4 adverse events, changes in CD4+ cell counts, viral load and resistance, and process measures (e.g., liver function). The study was approved by local and national ethics and research committees and boards, and all participants gave written informed consent.</p>
</sec>
<sec id="section4-0272989X10397615">
<title>Outcome Measures</title>
<p>We collected HRQoL data at baseline; weeks 6, 12, and 24; and every 12 wk thereafter. Assessments included the community preference-based Health Utilities Index Mark 3 (HUI3) and EQ-5D, the EQ-5D visual analog scale (VAS), and the Medical Outcomes Study HIV Health Survey (MOS-HIV) physical health and mental health summary scores (PHS and MHS). US participants also completed the patient preference-based standard gamble (SG) and time tradeoff (TTO) methods. Preference-based scores assume health states equivalent to death equal 0 and states equivalent to full health equal 1; VAS and MOS-HIV scores are measured from 0 to 100, with higher scores indicating better health. Detailed instrument descriptions are reported elsewhere.<sup><xref ref-type="bibr" rid="bibr30-0272989X10397615">30</xref></sup></p>
<p>We also collected sociodemographic and clinical data at baseline, including age, sex, race, transmission risk groups (e.g., men who have sex with men [MSM] and injection drug use), employment status, and number of concomitant medications for prophylaxis or treatment of opportunistic infections.</p>
<p>We matched each baseline and quarterly follow-up HRQoL assessment to CD4+ cell count and HIV-1 viral load count data by date. If we did not find an exact match, we used a time-weighted average of the CD4+ or viral load lab values that immediately preceded and followed the HRQoL assessment. If we could not calculate a time-weighted average, we used either the preceding value or the value that immediately followed the HRQoL assessment. We performed variations of these methods and found no difference in the final results.</p>
<p>AIDS-defining events and non-AIDS serious adverse events were assessed at each follow-up visit. An independent and blinded endpoints review committee determined whether an event was an AIDS-defining event. The committee also reviewed deaths and serious adverse events for attribution.<sup><xref ref-type="bibr" rid="bibr15-0272989X10397615">15</xref></sup> We classified AIDS-defining events as severe if they matched any 1 of 14 events, (e.g., cytomegalovirus retinitis and Hodgkin’s lymphoma). We flagged HRQoL assessments as having at least 1 ongoing serious adverse event if the assessment fell between the start and resolution dates recorded for the serious adverse event(s). We also counted prior AIDS-defining events and serious adverse events for each patient and identified patients who died within 90 d following the assessment.</p>
</sec>
<sec id="section5-0272989X10397615">
<title>Statistical Analysis</title>
<p>Analyses were by intention to treat. We calculated descriptive statistics to describe the trial cohort by randomization group at baseline.</p>
<p>We tested for HRQoL differences between ART groups across time using longitudinal linear mixed-effects models (SAS PROC MIXED). We prespecified the use of mixed-effects models at the outset of our data analysis given our longitudinal data set, where any given subject has repeated assessments and thus correlated errors. Unlike an ordinary least squares model, a mixed-effects model does not assume that observations are independent and can measure both within- and between-person changes in HRQoL.<sup><xref ref-type="bibr" rid="bibr31-0272989X10397615">31</xref></sup> Each instrument’s model was adjusted for baseline HRQoL (expressed as a deviation from the baseline mean) and included centered indicator variables for group membership, an indicator variable for the first quarter (intended ART interruption duration), and interaction terms (ART group by first quarter indicator). Model results report the estimated change in mean HRQoL over follow-up. We also report the estimated change in mean HRQoL from baseline to the first quarter and from the first quarter to the end of follow-up, as well as estimates of the linear combination of coefficients needed to compare treatment groups. To better understand the changes in HRQoL that occurred during the first quarter, we used a generalized linear mixed model with a Poisson distribution and log link function to examine the association between randomization group and counts of serious adverse events and AIDS-defining events during the interruption period (first quarter of follow-up). Finally, we used a set of mixed-effects models, 1 per instrument, to test the association of clinical and sociodemographic characteristics with HRQoL scores.</p>
<p>We examined the patterns and mechanisms of missing data by reviewing plots of average HRQoL scores by time to dropout, average scores by time to death, and average scores by percentage missing over time. We also ran models to see if baseline characteristics predicted dropout and if patients with intermittent HRQoL assessments were different from other patients.<sup><xref ref-type="bibr" rid="bibr32-0272989X10397615">32</xref></sup> Finally, we examined covariates that were predictive of missing HRQoL assessments and found that severe AIDS-defining events and serious adverse events were positively associated with missing HRQoL assessments. We chose not to impute HRQoL scores and assumed data were missing at random after reviewing the aforementioned plots and other analyses and as there were no statistically significant differences in AIDS-defining events or serious adverse events between ART groups over the length of the trial.<sup><xref ref-type="bibr" rid="bibr16-0272989X10397615">16</xref></sup></p>
<p>For each instrument’s model, we used unstructured covariance matrices and included the person and time of each HRQoL assessment as random effects to control for unobserved differences between patients and for repeated observations. All other variables were included as fixed effects. Analyses were performed using SAS software version 9.1 (SAS Institute, Cary, NC), with all analyses reporting 2-tailed <italic>P</italic> values.</p>
</sec>
<sec id="section6-0272989X10397615">
<title>Role of the Funding Source</title>
<p>The Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Cooperative Studies Program, the UK Medical Research Council, the Canadian Institutes for Health Research, and external experts reviewed and approved the design and conduct of the trial but had no role in the writing of this report.</p>
</sec>
</sec>
<sec id="section7-0272989X10397615" sec-type="results">
<title>Results</title>
<sec id="section8-0272989X10397615">
<title>Baseline Characteristics</title>
<p>A total of 368 patients were enrolled. Most were randomized to the 2 × 2 factorial (<italic>n</italic> = 339), with the remaining 29 patients (UK only) randomized to intensified ART or standard ART only. The mean age of the patients was 47.5 y, 98.1% were male, and 39.1% were black. Almost half (47.6%) reported being MSM and 14.1% reported injection drug use as risk groups. More than half (52.5%) claimed disability or other assistance. The median CD4+ cell count was 107 cells/mm<sup>3</sup>, and the median HIV-1 viral load was 4.8 log<sub>10</sub> copies/mL.</p>
</sec>
<sec id="section9-0272989X10397615">
<title>HRQoL</title>
<p>Of 6978 scheduled assessments, 5141 (74%) HRQoL assessments were completed using 6 instruments for a total of 28 827 scores over 6.25 y of quarterly follow-up (median follow-up time was 3.2 y). Of 4774 postbaseline assessments, between 93% and 95% of the assessments included HUI3, EQ-5D, VAS, or MOS-HIV PHS and MHS scores. About 83% of the US cohort’s assessments included SG and TTO scores, with the slightly higher rate of missing data attributable to technical difficulties with the assessment software.<sup><xref ref-type="bibr" rid="bibr30-0272989X10397615">30</xref></sup> Close to one-third (32%, <italic>n</italic> = 1545) of the assessments occurred when patients’ HIV viral loads registered above 4.7 log<sub>10</sub> copies/mL or 50 000 copies/mL, whereas 23% (<italic>n</italic> = 1078) took place when CD4+ cell counts were below 50 cells/mm<sup>3</sup>.</p>
</sec>
<sec id="section10-0272989X10397615">
<title>Effect of ART Strategies on HRQoL</title>
<p>At baseline, HRQoL scores (<italic>n</italic> = 367) were similar across ART groups (<xref ref-type="table" rid="table1-0272989X10397615">Table 1</xref>). There were no sustained differences in HRQoL among groups (<xref ref-type="table" rid="table2-0272989X10397615">Table 2</xref>; <xref ref-type="fig" rid="fig1-0272989X10397615">Figures 1</xref> and <xref ref-type="fig" rid="fig2-0272989X10397615">2</xref>). <xref ref-type="table" rid="table2-0272989X10397615">Table 2</xref> displays regression coefficients from our model of the effect of time and treatment management strategy on HRQoL. There were no significant sustained differences between patients randomized to treatment interruption versus no interruption or ART intensification versus standard ART, nor were there any significant interaction differences between the management strategies.</p>
<table-wrap id="table1-0272989X10397615" position="float">
<label>Table 1</label>
<caption>
<p>Baseline Characteristics by Management Strategy Assignment in the OPTIMA Trial<sup><xref ref-type="table-fn" rid="table-fn2-0272989X10397615">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table1-0272989X10397615" xlink:href="10.1177_0272989X10397615-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">No Treatment Interruption (<italic>n</italic> = 175)</th>
<th align="center">Treatment Interruption (<italic>n</italic> = 164)</th>
<th align="center">Standard ART (<italic>n</italic> = 192)</th>
<th align="center">Intensified ART (<italic>n</italic> = 176)</th>
<th align="center">Total Cohort (<italic>n</italic> = 368)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (SD), y</td>
<td>48 (8.5)</td>
<td>48.2 (8.3)</td>
<td>47.9 (8.6)</td>
<td>47.1 (8.3)</td>
<td>47.5 (8.5)</td>
</tr>
<tr>
<td>Male, %</td>
<td>98.3</td>
<td>97.6</td>
<td>98.4</td>
<td>97.7</td>
<td>98.1</td>
</tr>
<tr>
<td colspan="6">Race, %</td>
</tr>
<tr>
<td> White</td>
<td>49.7</td>
<td>44.5</td>
<td>46.9</td>
<td>51.1</td>
<td>48.9</td>
</tr>
<tr>
<td> Black</td>
<td>40.6</td>
<td>40.9</td>
<td>41.7</td>
<td>36.4</td>
<td>39.1</td>
</tr>
<tr>
<td> Other</td>
<td>9.7</td>
<td>14.6</td>
<td>11.5</td>
<td>12.5</td>
<td>12</td>
</tr>
<tr>
<td colspan="6">Mode of transmission, %</td>
</tr>
<tr>
<td> Men who have sex with men</td>
<td>45.1</td>
<td>46.3</td>
<td>45.3</td>
<td>50</td>
<td>47.6</td>
</tr>
<tr>
<td> Injection drugs</td>
<td>15.4</td>
<td>14.6</td>
<td>14.1</td>
<td>14.2</td>
<td>14.1</td>
</tr>
<tr>
<td colspan="6">Employment, %</td>
</tr>
<tr>
<td> Full- or part-time</td>
<td>25.9</td>
<td>26.1</td>
<td>27.4</td>
<td>26.4</td>
<td>26.9</td>
</tr>
<tr>
<td> Disability or other assistance</td>
<td>54.6</td>
<td>53.4</td>
<td>55.3</td>
<td>49.4</td>
<td>52.5</td>
</tr>
<tr>
<td> Unemployed</td>
<td>12.1</td>
<td>11.8</td>
<td>10.5</td>
<td>14.9</td>
<td>12.6</td>
</tr>
<tr>
<td> Other</td>
<td>7.5</td>
<td>8.7</td>
<td>6.8</td>
<td>9.2</td>
<td>8</td>
</tr>
<tr>
<td>Median concomitant medications (IQR)</td>
<td>2 (2–4)</td>
<td>2 (1–3)</td>
<td>2 (1–3)</td>
<td>2 (2–4)</td>
<td>2 (1–3)</td>
</tr>
<tr>
<td>Median CD4+ cells/mm<sup>3</sup> (IQR)</td>
<td>111 (35–195)</td>
<td>110 (35–199)</td>
<td>110 (37–191)</td>
<td>104 (31–188)</td>
<td>107 (35–188)</td>
</tr>
<tr>
<td>Median log<sub>10</sub> HIV viral load copies/mL (IQR)</td>
<td>4.8 (4.4–5.2)</td>
<td>4.8 (4.2–5.2)</td>
<td>4.8 (4.3–5.1)</td>
<td>4.9 (4.3–5.3)</td>
<td>4.8 (4.3–5.2)</td>
</tr>
<tr>
<td colspan="6">Mean HRQoL score (SD)<sup><xref ref-type="table-fn" rid="table-fn3-0272989X10397615">b</xref></sup></td>
</tr>
<tr>
<td> Health Utilities Index Mark 3</td>
<td>0.57 (0.32)</td>
<td>0.61 (0.30)</td>
<td>0.58 (0.32)</td>
<td>0.61 (0.32)</td>
<td>0.59 (0.32)</td>
</tr>
<tr>
<td> EQ-5D</td>
<td>0.76 (0.20)</td>
<td>0.79 (0.17)</td>
<td>0.76 (0.19)</td>
<td>0.79 (0.18)</td>
<td>0.77 (0.19)</td>
</tr>
<tr>
<td> Standard gamble<sup><xref ref-type="table-fn" rid="table-fn4-0272989X10397615">c</xref></sup></td>
<td>0.74 (0.31)</td>
<td>0.76 (0.27)</td>
<td>0.73 (0.31)</td>
<td>0.77 (0.27)</td>
<td>0.75 (0.29)</td>
</tr>
<tr>
<td> Time tradeoff<sup><xref ref-type="table-fn" rid="table-fn4-0272989X10397615">c</xref></sup></td>
<td>0.81 (0.29)</td>
<td>0.78 (0.33)</td>
<td>0.79 (0.32)</td>
<td>0.81 (0.30)</td>
<td>0.80 (0.31)</td>
</tr>
<tr>
<td> Visual analog scale</td>
<td>64.0 (22.6)</td>
<td>69.8 (18.9)</td>
<td>64.4 (21.6)</td>
<td>67.5 (21.2)</td>
<td>65.9 (21.5)</td>
</tr>
<tr>
<td colspan="6">Medical Outcomes Study HIV Health Survey</td>
</tr>
<tr>
<td> Physical Health Summary Score</td>
<td>41.1 (10.8)</td>
<td>42.4 (10.7)</td>
<td>41.5 (10.2)</td>
<td>42.1 (11.8)</td>
<td>41.8 (11.0)</td>
</tr>
<tr>
<td> Mental Health Summary Score</td>
<td>43.7 (12.1)</td>
<td>46.2 (9.9)</td>
<td>44.4 (11.8)</td>
<td>45.2 (10.6)</td>
<td>44.8 (11.2)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0272989X10397615">
<p>Note: ART = antiretroviral therapy; IQR = interquartile range.</p>
</fn>
<fn id="table-fn2-0272989X10397615">
<label>a.</label>
<p>A total of 339 patients were randomized to the 2 × 2 factorial; 29 patients were randomized to standard versus intensified ART only.</p>
</fn>
<fn id="table-fn3-0272989X10397615">
<label>b.</label>
<p>HRQoL data exclude 1 patient in the standard ART arm who missed all HRQoL assessments.</p>
</fn>
<fn id="table-fn4-0272989X10397615">
<label>c.</label>
<p>The standard gamble and time tradeoff were administered to US patients only (<italic>n</italic> = 288).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0272989X10397615" position="float">
<label>Table 2</label>
<caption>
<p>Effect of Time and Treatment Management Strategy (Treatment Interruption, ART Intensification, or Both) on Health-Related Quality of Life in the OPTIMA Trial<sup><xref ref-type="table-fn" rid="table-fn6-0272989X10397615">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table2-0272989X10397615" xlink:href="10.1177_0272989X10397615-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">HUI3 (<italic>n</italic> = 4252)</th>
<th align="center">EQ-5D (<italic>n</italic> = 4387)</th>
<th align="center">SG (<italic>n</italic> = 2839)</th>
<th align="center">TTO (<italic>n</italic> = 2861)</th>
<th align="center">VAS (<italic>n</italic> = 4453)</th>
<th align="center">PHS (<italic>n</italic> = 4278)</th>
<th align="center">MHS (<italic>n</italic> = 4278)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept</td>
<td>0.63<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">***</xref></td>
<td>0.78<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">***</xref></td>
<td>0.80<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">***</xref></td>
<td>0.80<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">***</xref></td>
<td>68.5<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">***</xref></td>
<td>43.3<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">***</xref></td>
<td>46.9<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">***</xref></td>
</tr>
<tr>
<td>Time, y</td>
<td>−0.02<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">***</xref></td>
<td>−0.01<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">***</xref></td>
<td>0.004</td>
<td>0.004</td>
<td>−0.6<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">*</xref></td>
<td>−1.1<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">***</xref></td>
<td>−0.5<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">**</xref></td>
</tr>
<tr>
<td>ART interruption</td>
<td>−0.02</td>
<td>−0.01</td>
<td>0.02</td>
<td>0.05<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">**</xref></td>
<td>−0.5</td>
<td>−0.2</td>
<td>−0.6</td>
</tr>
<tr>
<td>ART intensification</td>
<td>−0.01</td>
<td>−0.01</td>
<td>0.0002</td>
<td>0.02</td>
<td>−2.0</td>
<td>−1.3</td>
<td>−1.4<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">*</xref></td>
</tr>
<tr>
<td>ART interruption and intensification</td>
<td>−0.03</td>
<td>0.004</td>
<td>−0.05</td>
<td>0.02</td>
<td>−2.5</td>
<td>−1.9</td>
<td>0.8</td>
</tr>
<tr>
<td>First quarter</td>
<td>−0.01</td>
<td>−0.002</td>
<td>−0.01</td>
<td>0.02</td>
<td>0.04</td>
<td>−0.4</td>
<td>−0.1</td>
</tr>
<tr>
<td>ART interruption × first quarter</td>
<td>−0.03</td>
<td>−0.01</td>
<td>0.04</td>
<td>−0.04</td>
<td>−5.4<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">***</xref></td>
<td>−2.7<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">***</xref></td>
<td>−1.3<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">*</xref></td>
</tr>
<tr>
<td>ART intensification × first quarter</td>
<td>0.0004</td>
<td>0.02</td>
<td>0.01</td>
<td>0.04</td>
<td>−0.7</td>
<td>1.4<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">**</xref></td>
<td>0.3</td>
</tr>
<tr>
<td>ART interruption and intensification × first quarter</td>
<td>0.05</td>
<td>0.01</td>
<td>0.05</td>
<td>−0.03</td>
<td>−1.3</td>
<td>0.8</td>
<td>−1.7</td>
</tr>
<tr>
<td>Deviation from the baseline mean</td>
<td>0.68<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">***</xref></td>
<td>0.55<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">***</xref></td>
<td>0.36<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">***</xref></td>
<td>0.35<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">***</xref></td>
<td>0.5<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">***</xref></td>
<td>0.7<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">***</xref></td>
<td>0.7<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">***</xref></td>
</tr>
<tr>
<td colspan="8">Linear combination of coefficients</td>
</tr>
<tr>
<td colspan="8"> First quarter</td>
</tr>
<tr>
<td>  ART interruption v. no interruption</td>
<td>−0.05<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">*</xref></td>
<td>−0.02</td>
<td>0.05</td>
<td>0.01</td>
<td>−5.9<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">**</xref></td>
<td>−2.9<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">**</xref></td>
<td>−1.9<xref ref-type="table-fn" rid="table-fn7-0272989X10397615">*</xref></td>
</tr>
<tr>
<td>  ART intensification v. standard ART</td>
<td>−0.01</td>
<td>0.01</td>
<td>0.01</td>
<td>0.06</td>
<td>−2.7</td>
<td>0.1</td>
<td>−1.0</td>
</tr>
<tr>
<td>  ART interruption and intensification v. neither</td>
<td>0.02</td>
<td>0.01</td>
<td>−0.01</td>
<td>−0.004</td>
<td>−3.8</td>
<td>−1.1</td>
<td>−0.9</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0272989X10397615">
<p>Note: ART = antiretroviral treatment.</p>
</fn>
<fn id="table-fn6-0272989X10397615">
<label>a.</label>
<p>Regression coefficients shown. Health Utilities Index Mark 3 (HUI3), EQ-5D, standard gamble (SG), time trade-off (TTO), EQ-5D visual analog scale (VAS), Medical Outcomes Study HIV Health Survey (MOS-HIV) Physical Health Summary Score (PHS), Mental Health Summary Score (MHS). Scale range: HUI3 (–0.36 to 1); EQ-5D (–0.59 to 1); SG (0–1); TTO (0–1); VAS (0–100); MOS-HIV PHS and MHS (0–100).</p>
</fn>
<fn id="table-fn7-0272989X10397615">
<label>*</label>
<p><italic>P</italic> ≤ 0.05. **<italic>P</italic> &lt; 0.01. ***<italic>P</italic> &lt; 0.001.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig1-0272989X10397615" position="float">
<label>Figure 1</label>
<caption>
<p>Mean change in health-related quality of life (HRQoL) scores over time by antiretroviral therapy (ART) interruption assignment in the OPTIMA trial. The graphs show unadjusted mean change from baseline in HRQoL scores over time for each instrument, stratified by ART interruption assignment (interruption v. no interruption). Scale range: HUI3 (−0.36 to 1), EQ-5D (−0.59 to 1), SG (0–1), TTO (0–1), VAS (0–100), MOS-HIV PHS and MHS (0–100). Across all instruments, higher scores reflect better HRQoL. Error bars represent 95% confidence intervals and are shown as 1 sided for clarity.</p>
</caption>
<graphic xlink:href="10.1177_0272989X10397615-fig1.tif"/>
</fig>
<fig id="fig2-0272989X10397615" position="float">
<label>Figure 2</label>
<caption>
<p>Mean change in health-related quality of life (HRQoL) scores over time by antiretroviral therapy (ART) intensification assignment in the OPTIMA trial. The graphs show unadjusted mean change from baseline in HRQoL scores over time for each instrument, stratified by ART intensification assignment (ART intensification v. standard ART). Scale range: HUI3 (−0.36 to 1), EQ-5D (−0.59 to 1), SG (0–1), TTO (0–1), VAS (0–100), MOS-HIV PHS and MHS (0–100). Across all instruments, higher scores reflect better HRQoL. Error bars represent 95% confidence intervals and are shown as 1 sided for clarity.</p>
</caption>
<graphic xlink:href="10.1177_0272989X10397615-fig2.tif"/>
</fig>
<p>We found small annual declines in HRQoL scores (HUI3 −0.02, <italic>P</italic> &lt; 0.001; EQ-5D −0.01, <italic>P</italic> &lt; 0.001; VAS −0.6, <italic>P</italic> = 0.03; PHS −1.1, <italic>P</italic> &lt; 0.001; MHS −0.5, <italic>P</italic> = 0.003). Mortality rates were 7% in year 1, 10% in year 2, and 9% in year 3. For most survivors, quality of life did not decline by a clinically significant amount. We considered a clinically significant decline in HRQoL to be a decrease of 0.05 from the baseline EQ-5D. We applied this definition to survivors who completed a quality of life assessment and found that 75% did not have a clinically significant decline in quality of life at year 1, 70% did not decline by year 2, and 70% had no significant decline by year 3.</p>
<p>We also found a significant but transient 	first quarter decline in HRQoL scores among interruption patients for HUI3 −0.05, <italic>P</italic> = 0.03; VAS −5.9, <italic>P</italic> = 0.002; PHS −2.9, <italic>P</italic> = 0.001; and MHS −1.9, <italic>P</italic> = 0.02 (<xref ref-type="table" rid="table2-0272989X10397615">Table 2</xref>). We considered whether there were corresponding clinical events related to this decline and found that those randomized to the treatment interruption had significantly more serious adverse events during the first quarter compared with the control group (<italic>P</italic> = 0.03; not shown). There were no differences in the number of AIDS-defining events between the groups during the first quarter.</p>
</sec>
<sec id="section11-0272989X10397615">
<title>Response of Instruments to Clinical and Sociodemographic Factors</title>
<p>Clinical events were closely associated with changes in HRQoL throughout follow-up and had a greater impact than group assignment. <xref ref-type="table" rid="table3-0272989X10397615">Table 3</xref> shows the results of regressions from models of the effect of clinical and demographic characteristics on HRQoL. A significant and substantial negative impact on HRQoL (HUI3, −0.12, <italic>P</italic> &lt; 0.001; EQ-5D, −0.11, <italic>P</italic> &lt; 0.001; VAS, −7.2, <italic>P</italic> &lt; 0.001; PHS, −3.4, <italic>P</italic> &lt; 0.001; MHS, −3.4, <italic>P</italic> &lt; 0.001) was found in assessments preceding death within 90 d. Low CD4+ cell counts and the presence of at least 1 ongoing serious adverse event also had significant and substantial effects on scores from all 6 HRQoL measures throughout follow-up. A patient with a CD4+ cell count at or below 50 cells/mm<sup>3</sup> had a 0.04 lower HUI3 score than a patient with greater than 100 CD4+ cells/mm<sup>3</sup> (<italic>P</italic> &lt; 0.001). Having at least 1 ongoing serious adverse event was also associated with a lower score compared with patients without an ongoing serious adverse event (e.g., SG −0.08, <italic>P</italic> &lt; 0.001). Higher log<sub>10</sub> HIV viral load, CD4+ cell counts between 50 and 100 cells/mm<sup>3</sup>, prior serious adverse events, and prior severe AIDS-defining events were also significantly associated with lower HRQoL for some of the instruments. At least 1 prior serious adverse event was associated with a lower EQ-5D (−0.02, <italic>P</italic> = 0.01) score; at least 2 prior serious adverse events had an even larger effect (−0.04, <italic>P</italic> &lt; 0.001).</p>
<table-wrap id="table3-0272989X10397615" position="float">
<label>Table 3</label>
<caption>
<p>Effect of Clinical and Sociodemographic Characteristics on Health-Related Quality of Life in the OPTIMA Trial<sup><xref ref-type="table-fn" rid="table-fn8-0272989X10397615">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table3-0272989X10397615" xlink:href="10.1177_0272989X10397615-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">HUI3 (<italic>n</italic> = 4783)</th>
<th align="center">EQ-5D (<italic>n</italic> = 4852)</th>
<th align="center">SG (<italic>n</italic> = 3478)</th>
<th align="center">TTO (<italic>n</italic> = 3480)</th>
<th align="center">VAS (<italic>n</italic> = 4902)</th>
<th align="center">PHS (<italic>n</italic> = 4797)</th>
<th align="center">MHS (<italic>n</italic> = 4797)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept</td>
<td>0.61<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>0.75<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>0.74<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>0.76<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>69.5<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>42.6<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>47.9<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
</tr>
<tr>
<td colspan="8">Clinical characteristics</td>
</tr>
<tr>
<td> Death within 90 d</td>
<td>−0.12<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−0.11<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−0.04</td>
<td>−0.06</td>
<td>−7.2<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−3.4<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−3.4<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
</tr>
<tr>
<td> Log<sub>10</sub> HIV viral load copies/mL</td>
<td>−0.01<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−0.002</td>
<td>−0.01</td>
<td>−0.01</td>
<td>−1.0<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−0.5<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−0.6<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
</tr>
<tr>
<td> CD4 ≤ 50 cells/mm<sup>3</sup>
</td>
<td>−0.04<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−0.03<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−0.03<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">*</xref></td>
<td>−0.04<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">**</xref></td>
<td>−4.7<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−2.4<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−2.5<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
</tr>
<tr>
<td> 50 &lt; CD4 ≤ 100 cells/mm<sup>3</sup>
</td>
<td>−0.02<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">*</xref></td>
<td>−0.01</td>
<td>−0.02</td>
<td>−0.03<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">*</xref></td>
<td>−1.8<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">*</xref></td>
<td>−1.0<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">**</xref></td>
<td>−0.4</td>
</tr>
<tr>
<td> Serious adverse event, at least 1 ongoing</td>
<td>−0.07<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−0.06<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−0.08<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−0.05<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">*</xref></td>
<td>−4.8<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−4.5<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−2.7<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
</tr>
<tr>
<td> Serious adverse event, at least 1 prior</td>
<td>−0.03<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">**</xref></td>
<td>−0.02<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">*</xref></td>
<td>0.02</td>
<td>−0.01</td>
<td>−2.5<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−0.9<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">*</xref></td>
<td>−0.8<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">*</xref></td>
</tr>
<tr>
<td> Serious adverse event, 2 or more prior</td>
<td>−0.07<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−0.04<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>0.005</td>
<td>−0.02</td>
<td>−3.0<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−3.7<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>−2.1<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
</tr>
<tr>
<td> Severe AIDS-defining event, at least 1 prior</td>
<td>−0.05</td>
<td>−0.01</td>
<td>−0.08</td>
<td>0.005</td>
<td>−2.5</td>
<td>−2.7<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">*</xref></td>
<td>−1.6</td>
</tr>
<tr>
<td colspan="8">Race (reference, white)</td>
</tr>
<tr>
<td> Black</td>
<td>0.12<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>0.05<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">**</xref></td>
<td>0.09<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>0.12<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>5.3<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">**</xref></td>
<td>4.0<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">***</xref></td>
<td>2.6<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">*</xref></td>
</tr>
<tr>
<td> Other</td>
<td>0.08</td>
<td>0.05<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">*</xref></td>
<td>0.08<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">*</xref></td>
<td>0.08<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">*</xref></td>
<td>8.9<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">**</xref></td>
<td>4.3<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">**</xref></td>
<td>1.8</td>
</tr>
<tr>
<td colspan="8">Mode of transmission</td>
</tr>
<tr>
<td> Men who have sex with men</td>
<td>0.06<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">*</xref></td>
<td>0.05<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">**</xref></td>
<td>0.05</td>
<td>0.05<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">*</xref></td>
<td>4.1<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">*</xref></td>
<td>2.9<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">*</xref></td>
<td>1.5</td>
</tr>
<tr>
<td> Injection drug use</td>
<td>−0.08</td>
<td>−0.05<xref ref-type="table-fn" rid="table-fn9-0272989X10397615">*</xref></td>
<td>0.05</td>
<td>0.04</td>
<td>−0.7</td>
<td>−2.5</td>
<td>−0.8</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn8-0272989X10397615">
<label>a.</label>
<p>Regression coefficients shown. Health Utilities Index Mark 3 (HUI3), EQ-5D, standard gamble (SG), time tradeoff (TTO), EQ-5D visual analog scale (VAS), Medical Outcomes Study HIV Health Survey (MOS-HIV) Physical Health Summary Score (PHS) and Mental Health Summary Score (MHS). Scale range: HUI3 (–0.36 to 1), EQ-5D (–0.59 to 1), SG (0–1), TTO (0–1), VAS (0–100), MOS-HIV PHS and MHS (0–100).</p>
</fn>
<fn id="table-fn9-0272989X10397615">
<label>*</label>
<p><italic>P</italic> ≤ 0.05. **<italic>P</italic> &lt; 0.01. ***<italic>P</italic> &lt; 0.001.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Sociodemographic characteristics were also associated with HRQoL (<xref ref-type="table" rid="table3-0272989X10397615">Table 3</xref>). Black patients had significantly higher HRQoL scores compared with white patients, after controlling for all other factors (HUI3, 0.12, <italic>P</italic> &lt; 0.001; EQ-5D, 0.05, <italic>P</italic> = 0.004; SG, 0.09, <italic>P</italic> &lt; 0.001; TTO, 0.12, <italic>P</italic> &lt; 0.001; VAS, 5.3, <italic>P</italic>= 0.009; PHS, 4, <italic>P</italic> &lt; 0.001; MHS, 2.6, <italic>P</italic> = 0.02). Infection by MSM contact was also significantly related to HRQoL, with greater HUI3 (0.06, <italic>P</italic> = 0.05), EQ-5D (0.05, <italic>P</italic> = 0.007), TTO (0.05, <italic>P</italic> = 0.05), VAS (4.1, <italic>P</italic> = 0.04), and PHS scores (2.9, <italic>P</italic> = 0.01).</p>
</sec>
</sec>
<sec id="section12-0272989X10397615" sec-type="discussion">
<title>Discussion</title>
<p>Our study provides the most comprehensive long-term longitudinal assessment of HRQoL in patients who have advanced HIV disease to date. We used several descriptive and preference-based instruments to assess HRQoL. To our knowledge, our analysis is also the first effort to assess the impact of treatment interruption and ART intensification on both descriptive and preference-based assessments of HRQoL in the setting of MDR HIV and AIDS. We found there were no sustained changes in HRQoL from either treatment interruption or intensification. Patients assigned to a treatment interruption did experience a transient small decrement in HRQoL as assessed by the HUI3, a preference-based measure, the VAS, and by the MOS-HIV, but not by other measures of HRQoL. A modest decrement in HRQoL during the treatment interruption is plausible because these patients had an expected drop in CD4+ cell count (not shown) and also reported more serious adverse events than did patients without an interruption. However, the magnitude of the average decrement may be of little clinical significance. Our findings are notable because of concerns that intensification of ART might worsen quality of life and the hope that a treatment interruption might improve HRQoL by reducing toxicity from ART. Neither of these changes in HRQoL was observed in this long-term trial.</p>
<p>Our second main finding was that variations in HRQoL reflected clinically significant events. Patients with CD4+ cell counts ≤50 cells/mm<sup>3</sup> or at least 1 ongoing serious adverse event had significantly worse HRQoL over time and across 6 instruments. These findings reveal the responsiveness of these measures and are consistent with previous studies.<sup><xref ref-type="bibr" rid="bibr30-0272989X10397615">30</xref>,<xref ref-type="bibr" rid="bibr33-0272989X10397615">33</xref>–<xref ref-type="bibr" rid="bibr35-0272989X10397615">35</xref></sup> Patients who died within 90 d following the assessment, or who had prior serious adverse events, also had worse HUI3, EQ-5D, VAS, PHS, and MHS scores over time.<sup><xref ref-type="bibr" rid="bibr19-0272989X10397615">19</xref>,<xref ref-type="bibr" rid="bibr33-0272989X10397615">33</xref>,<xref ref-type="bibr" rid="bibr35-0272989X10397615">35</xref></sup> Imminent death resulted in significantly lower HRQoL, with HUI3 scores 0.12 lower compared with those who did not die within 90 d of the assessment. A log<sub>10</sub> increase in viral load was associated with a decline in HRQoL on some measures, but not all.</p>
<p>Our third main finding was that there was little decline in average HRQoL among the survivors in more than 4 y of follow-up. Quality of life can be maintained for many patients, even those with advanced and MDR disease; however, this finding is tempered by the fact that more than one-third of patients died and were censored from the estimates of HRQoL.</p>
<p>Prior studies that have evaluated the impact of treatment interruptions on HRQoL have shown mostly null findings, with the largest trial reporting a detrimental effect on HRQoL.<sup><xref ref-type="bibr" rid="bibr19-0272989X10397615">19</xref>–<xref ref-type="bibr" rid="bibr29-0272989X10397615">29</xref></sup> Two observational studies found no effect of treatment interruptions on HRQoL, as assessed by the MOS-HIV and other descriptive measures.<sup><xref ref-type="bibr" rid="bibr25-0272989X10397615">25</xref>,<xref ref-type="bibr" rid="bibr28-0272989X10397615">28</xref></sup> Most clinical trials also failed to detect any effect. Neither continuous, cyclic, nor CD4 count–guided treatment interruptions produced any detectable long-term effect on HRQoL using descriptive instruments in several studies.<sup><xref ref-type="bibr" rid="bibr21-0272989X10397615">21</xref>–<xref ref-type="bibr" rid="bibr24-0272989X10397615">24</xref>,<xref ref-type="bibr" rid="bibr26-0272989X10397615">26</xref></sup> The largest of the trials, SMART, enrolled 1225 HIV+ patients in a QOL substudy.<sup><xref ref-type="bibr" rid="bibr19-0272989X10397615">19</xref></sup> Results showed a decrement in SF-12 and VAS-assessed HRQoL scores in patients assigned to CD4 count–guided interruptions. The impact on HRQoL may have been more pronounced in SMART patients who had higher median CD4+ cell counts (575 cells/mm<sup>3</sup>) and were likely healthier than OPTIMA patients. In contrast to previous research, OPTIMA is the only trial to our knowledge to assess changes in HRQoL with treatment interruption using preference-based instruments.</p>
<p>Previous studies have assessed the association between ART and HRQoL in advanced and ART-experienced HIV patients. Several clinical trials found that adding an additional antiretroviral to an existing 2-drug regimen or multidrug regimen maintained MOS-HIV scores.<sup><xref ref-type="bibr" rid="bibr36-0272989X10397615">36</xref>–<xref ref-type="bibr" rid="bibr39-0272989X10397615">39</xref></sup> The OPTIMA study is the first to compare the impact of conventional combination therapy with intensification of ART on HRQoL in MDR HIV patients using descriptive and preference-based instruments. We found no long-term difference in the effect on HRQoL between the treatment strategies.</p>
<p>Our findings that self-designation of black race or infection by MSM contact were associated with higher HRQoL are consistent with other studies.<sup><xref ref-type="bibr" rid="bibr34-0272989X10397615">34</xref>,<xref ref-type="bibr" rid="bibr40-0272989X10397615">40</xref>–<xref ref-type="bibr" rid="bibr47-0272989X10397615">47</xref></sup> Cotton and others showed that spirituality is an important factor in HIV patients’ lives, particularly in African American patients who, unlike white patients, were more likely to use positive religious coping strategies; moreover, increasing levels of spirituality were associated with better HRQoL outcomes.<sup><xref ref-type="bibr" rid="bibr44-0272989X10397615">44</xref>,<xref ref-type="bibr" rid="bibr45-0272989X10397615">45</xref></sup> In a study of patients infected with HIV, Mrus and others<sup><xref ref-type="bibr" rid="bibr46-0272989X10397615">46</xref></sup> found that spirituality was positively associated with rating scale and TTO scores. Previous studies found that MSM HIV patients had a better rating scale and functional status scores compared with non-MSM patients.<sup><xref ref-type="bibr" rid="bibr43-0272989X10397615">43</xref>,<xref ref-type="bibr" rid="bibr46-0272989X10397615">46</xref>,<xref ref-type="bibr" rid="bibr47-0272989X10397615">47</xref></sup> Future studies are needed to explore why MSM patients experienced better HRQoL scores compared with non-MSM patients.</p>
<p>Our study used several instruments to assess HRQoL. The SG and TTO methods of utility assessment were not as responsive to clinical events as compared with the HUI3 and EQ-5D. This finding may be due in part to the differences between direct (SG and TTO) and indirect (HUI3 and EQ-5D) measures. Direct measures ask patients to assess and assign a value to their current health, whereas indirect measures ask patients to assess their current health using descriptive questions, which are then valued using community-based preferences. Previous studies suggest that direct methods allow patients to value their health status as being composed of more than that which is reflected by the dimensions included in the HUI3 or EQ-5D.<sup><xref ref-type="bibr" rid="bibr48-0272989X10397615">48</xref>–<xref ref-type="bibr" rid="bibr50-0272989X10397615">50</xref></sup> Furthermore, these studies suggest that indirect measures, by use of community-based preferences, may suppress heterogeneity among patients—	heterogeneity that is accurately reflected by direct measures. Also of note, the use of SG and TTO was more resource intensive in our trial because they were administered via computer-based interview. Thus, the choice of instrument to assess HRQoL may vary depending on the purpose of the assessment, whether direct or indirect measures are desirable, and the resources available.</p>
<p>Our study has limitations. Missing quality of life data may have biased our results. However, we consider this unlikely after examining the patterns of missing data and because the primary and secondary clinical outcomes (AIDS-defining events, serious adverse events, and death) were not significantly different between the randomized groups.<sup><xref ref-type="bibr" rid="bibr16-0272989X10397615">16</xref></sup> The results of this study may not apply to ART-naïve or other HIV patients who have not experienced multiple treatment failures or who have not developed MDR HIV or AIDS. In addition, almost all OPTIMA participants were men; women may differ in their HRQoL scores and determinants of HRQoL. Although a plausible explanation of why we did not observe differences by management strategy is that our cohort was homogeneous and represented only advanced disease, the average rating of HRQoL was relatively similar to that found in studies of patients with earlier stage disease.<sup><xref ref-type="bibr" rid="bibr30-0272989X10397615">30</xref></sup> Another explanation is that we used unresponsive instruments to measure HRQoL; however, our finding of substantial associations between HRQoL and clinical factors argue against this interpretation. Finally, in our examination of the relationship between treatment group and HRQoL, as well as several sociodemographic and clinical characteristics and HRQoL, we did not formally adjust for multiple comparisons. We did, however, provide <italic>P</italic> value ranges to better understand the degree of statistical significance.</p>
<p>In this long-term trial, we found a transient 12-wk decline in HRQoL among those randomized to treatment interruption but no sustained differences between management strategy groups during follow-up. Our findings suggest that very advanced disease, as indicated by low CD4+ cell count, the presence of ongoing or prior serious adverse events, or death within 90 d, were all significantly associated with lower HRQoL scores. Finally, this study found that among those who survived, quality of life can be maintained in patients with advanced MDR HIV disease.</p>
</sec>
</body>
<back>
<ack>
<p>Dr. Cameron is supported by a Career Scientist Award of the Ontario HIV Treatment Network, Ontario Ministry of Health. We thank the investigators and staff at the participating sites. We also thank Dr. Diane Fairclough for her expertise in missing data analysis techniques and longitudinal modeling.</p>
<sec id="section13-0272989X10397615">
<title>Trial Management Committee</title>
<p>Martin Schechter, MD (Co-Chair); Lawrence Deyton, MD (Co-Chair); Janet Darbyshire, OBE, MD, FRCP (Co-Chair); Sheldon Brown, MD; Mark Holodniy, MD; Tassos Kyriakides, PhD; Douglas Owens, MD; Wei Yu, PhD; D. William Cameron, MD; Joel Singer, PhD; Aslam Anis, PhD; Brian Gazzard, MD, FRCP; Mike Youle, MD; Malcolm Hooker, MD; Abdel Babiker, PhD; and Mark Sculpher, PhD.</p>
</sec>
<sec id="section14-0272989X10397615">
<title>Trial Steering Committee</title>
<p>Sir Alasdair Breckenridge (Chair); Kevin Schulman, MD; Paul Volberding, MD; Mark Wainberg, PhD; Don MacIver; Simon Collins; and Maggie Atkinson.</p>
</sec>
<sec id="section15-0272989X10397615">
<title>Data and Safety Monitoring Board</title>
<p>Dame Anne McClaren (Chair, deceased); Deborah Cotton, MD, MPH; Vern Farewell, PhD; Mary Foulkes, PhD; Andreas Laupacis, PhD; and Jorge Tavel, MD.</p>
</sec>
<sec id="section16-0272989X10397615">
<title>Endpoints Review Committee</title>
<p>Richard Davey Jr., MD (Chair); Brian Gazzard, MD, FRCP; Mike Youle, MB, ChB; D. William Cameron, MD; Sheldon T. Brown, MD; Mark Holodniy, MD; and Tim Peto, MD.</p>
</sec>
<sec id="section17-0272989X10397615">
<title>Trinational Funders Committee</title>
<p>John Feussner, MD; Isabelle Schmid, PhD; Joe McNamara, PhD; and Grant D. Huang, MPH, PhD.</p>
</sec>
</ack>
<fn-group>
<fn fn-type="presented-at">
<p>Earlier versions of this work were presented at the Canadian Association for HIV Research Conference, Vancouver, Canada, April 2009 and at the Society for Medical Decision Making Annual Meeting, Los Angeles, California, October 2009.</p>
</fn>
<fn fn-type="supported-by">
<p>This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Cooperative Studies Program; the UK Medical Research Council; and the Canadian Institutes for Health Research. Options in Management with Antiretrovirals is the initial trial of the newly established trinational program involving the above 3 agencies.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. Primary funding source: Department of Veterans Affairs Cooperative Studies Program, the United Kingdom Medical Research Council, and the Canadian Institutes for Health Research. Trial registration: <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">http://clinicaltrials.gov</ext-link>, No. NCT00050089.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0272989X10397615">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hammer</surname><given-names>SM</given-names></name>
<name><surname>Squires</surname><given-names>KE</given-names></name>
<name><surname>Hughes</surname><given-names>MD</given-names></name>
<etal/>
</person-group>. <article-title>A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team</article-title>. <source>N Engl J Med</source>. <year>1997</year>;<volume>337</volume>(<issue>11</issue>):<fpage>725</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr2-0272989X10397615">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hogg</surname><given-names>RS</given-names></name>
<name><surname>Heath</surname><given-names>KV</given-names></name>
<name><surname>Yip</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Improved survival among HIV-infected individuals following initiation of antiretroviral therapy</article-title>. <source>JAMA</source>. <year>1998</year>;<volume>279</volume>(<issue>6</issue>):<fpage>450</fpage>–<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr3-0272989X10397615">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Palella</surname><given-names>FJ</given-names><suffix>Jr</suffix></name>
<name><surname>Delaney</surname><given-names>KM</given-names></name>
<name><surname>Moorman</surname><given-names>AC</given-names></name>
<etal/>
</person-group>. <article-title>Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators</article-title>. <source>N Engl J Med</source>. <year>1998</year>;<volume>338</volume>(<issue>13</issue>):<fpage>853</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr4-0272989X10397615">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Paterson</surname><given-names>DL</given-names></name>
<name><surname>Swindells</surname><given-names>S</given-names></name>
<name><surname>Mohr</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Adherence to protease inhibitor therapy and outcomes in patients with HIV infection</article-title>. <source>Ann Intern Med</source>. <year>2000</year>;<volume>133</volume>(<issue>1</issue>):<fpage>21</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr5-0272989X10397615">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Phillips</surname><given-names>AN</given-names></name>
<name><surname>Staszewski</surname><given-names>S</given-names></name>
<name><surname>Lampe</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Human immunodeficiency virus rebound after suppression to &lt;400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression</article-title>. <source>J Infect Dis</source>. <year>2002</year>;<volume>186</volume>(<issue>8</issue>):<fpage>1086</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr6-0272989X10397615">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mocroft</surname><given-names>A</given-names></name>
<name><surname>Ledergerber</surname><given-names>B</given-names></name>
<name><surname>Viard</surname><given-names>JP</given-names></name>
<etal/>
</person-group>. <article-title>Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group</article-title>. <source>J Infect Dis</source>. <year>2004</year>;<volume>190</volume>(<issue>11</issue>):<fpage>1947</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr7-0272989X10397615">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sabin</surname><given-names>CA</given-names></name>
<name><surname>Hill</surname><given-names>T</given-names></name>
<name><surname>Lampe</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study</article-title>. <source>BMJ</source>. <year>2005</year>;<volume>330</volume>(<issue>7493</issue>):<fpage>695</fpage>.</citation>
</ref>
<ref id="bibr8-0272989X10397615">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cozzi-Lepri</surname><given-names>A</given-names></name>
<name><surname>Phillips</surname><given-names>AN</given-names></name>
<name><surname>Clotet</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study</article-title>. <source>AIDS</source>. <year>2008</year>;<volume>22</volume>(<issue>16</issue>):<fpage>2187</fpage>–<lpage>98</lpage>.</citation>
</ref>
<ref id="bibr9-0272989X10397615">
<label>9.</label>
<citation citation-type="gov">
<article-title>Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-	infected adults and adolescents</article-title>. <collab>Department of Health and Human Services</collab>. <comment>[December 1, 2009; cited October 19, 2010]. Available from: URL: <ext-link ext-link-type="uri" xlink:href="http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</ext-link></comment>
</citation>
</ref>
<ref id="bibr10-0272989X10397615">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Napravnik</surname><given-names>S</given-names></name>
<name><surname>Edwards</surname><given-names>D</given-names></name>
<name><surname>Stewart</surname><given-names>P</given-names></name>
<name><surname>Stalzer</surname><given-names>B</given-names></name>
<name><surname>Matteson</surname><given-names>E</given-names></name>
<name><surname>Eron</surname><given-names>JJ</given-names><suffix>Jr</suffix></name>
</person-group>. <article-title>HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2005</year>;<volume>40</volume>(<issue>1</issue>):<fpage>34</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr11-0272989X10397615">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cozzi-Lepri</surname><given-names>A</given-names></name>
<name><surname>Phillips</surname><given-names>AN</given-names></name>
<name><surname>Ruiz</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen</article-title>. <source>AIDS</source>. <year>2007</year>;<volume>21</volume>(<issue>6</issue>):<fpage>721</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr12-0272989X10397615">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rottmann</surname><given-names>C</given-names></name>
<name><surname>Miller</surname><given-names>V</given-names></name>
<name><surname>Staszewski</surname><given-names>S</given-names></name>
</person-group>. <article-title>Mega-HAART: preliminary results and correlation with baseline resistance</article-title>. <source>Antivir Ther</source>. <year>1999</year>;<volume>4</volume> <issue>Suppl 3</issue>:<fpage>93</fpage>–<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr13-0272989X10397615">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>V</given-names></name>
<name><surname>Cozzi-Lepri</surname><given-names>A</given-names></name>
<name><surname>Hertogs</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort</article-title>. <source>Antivir Ther</source>. <year>2000</year>;<volume>5</volume>(<issue>1</issue>):<fpage>49</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr14-0272989X10397615">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Montaner</surname><given-names>JS</given-names></name>
<name><surname>Harrigan</surname><given-names>PR</given-names></name>
<name><surname>Jahnke</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens</article-title>. <source>AIDS</source>. <year>2001</year>;<volume>15</volume>(<issue>1</issue>):<fpage>61</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr15-0272989X10397615">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kyriakides</surname><given-names>TC</given-names></name>
<name><surname>Babiker</surname><given-names>A</given-names></name>
<name><surname>Singer</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>An open-label randomized clinical trial of novel therapeutic strategies for HIV-	infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial</article-title>. <source>Control Clin Trials</source>. <year>2003</year>;<volume>24</volume>(<issue>4</issue>):<fpage>481</fpage>–<lpage>500</lpage>.</citation>
</ref>
<ref id="bibr16-0272989X10397615">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holodniy</surname><given-names>M</given-names></name>
<name><surname>Brown</surname><given-names>ST</given-names></name>
<name><surname>Cameron</surname><given-names>DW</given-names></name>
<etal/>
</person-group>. <article-title>OPTIMA Team. Results of antiretroviral treatment tnterruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA Trial</article-title>. <source>PLoS ONE</source>. <year>2011</year>; <comment>In press</comment>.</citation>
</ref>
<ref id="bibr17-0272989X10397615">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Revicki</surname><given-names>DA</given-names></name>
</person-group>. <article-title>Relationship between health utility and psychometric health status measures</article-title>. <source>Med Care</source>. <year>1992</year>;<volume>30</volume>(<issue>5 Suppl</issue>):<fpage>MS274</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr18-0272989X10397615">
<label>18.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Gold</surname><given-names>MR</given-names></name>
<name><surname>Siegel</surname><given-names>JE</given-names></name>
<name><surname>Russell</surname><given-names>LB</given-names></name>
<name><surname>Weinstein</surname><given-names>MC</given-names></name>
</person-group>. <source>Cost-Effectiveness in Health and Medicine</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>; <year>1996</year>.</citation>
</ref>
<ref id="bibr19-0272989X10397615">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Burman</surname><given-names>WJ</given-names></name>
<name><surname>Grund</surname><given-names>B</given-names></name>
<name><surname>Roediger</surname><given-names>MP</given-names></name>
<name><surname>Friedland</surname><given-names>G</given-names></name>
<name><surname>Darbyshire</surname><given-names>J</given-names></name>
<name><surname>Wu</surname><given-names>AW</given-names></name>
</person-group>. <article-title>The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2008</year>;<volume>47</volume>(<issue>2</issue>):<fpage>185</fpage>–<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr20-0272989X10397615">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krentz</surname><given-names>HB</given-names></name>
<name><surname>Gill</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>The impact on health-related quality of life of treatment interruptions in HIV-1-infected patients</article-title>. <source>AIDS</source>. <year>2003</year>;<volume>17</volume>(<issue>4</issue>):<fpage>631</fpage>–<lpage>3</lpage>.</citation>
</ref>
<ref id="bibr21-0272989X10397615">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lawrence</surname><given-names>J</given-names></name>
<name><surname>Hullsiek</surname><given-names>KH</given-names></name>
<name><surname>Thackeray</surname><given-names>LM</given-names></name>
<etal/>
</person-group>. <article-title>Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2006</year>;<volume>43</volume>(<issue>2</issue>):<fpage>169</fpage>–<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr22-0272989X10397615">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lawrence</surname><given-names>J</given-names></name>
<name><surname>Mayers</surname><given-names>DL</given-names></name>
<name><surname>Hullsiek</surname><given-names>KH</given-names></name>
<etal/>
</person-group>. <article-title>Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus</article-title>. <source>N Engl J Med</source>. <year>2003</year>;<volume>349</volume>(<issue>9</issue>):<fpage>837</fpage>–<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr23-0272989X10397615">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maserati</surname><given-names>R</given-names></name>
<name><surname>Foli</surname><given-names>A</given-names></name>
<name><surname>Tomasoni</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Effects of structured treatment interruptions on metabolic, anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAART</article-title>. <source>Curr HIV Res</source>. <year>2007</year>;<volume>5</volume>(<issue>3</issue>):<fpage>337</fpage>–<lpage>43</lpage>.</citation>
</ref>
<ref id="bibr24-0272989X10397615">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nuesch</surname><given-names>R</given-names></name>
<name><surname>Gayet-Ageron</surname><given-names>A</given-names></name>
<name><surname>Chetchotisakd</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>The impact of combination antiretroviral therapy and its interruption on anxiety, stress, depression and quality of life in Thai patients</article-title>. <source>Open AIDS J</source>. <year>2009</year>;<volume>3</volume>:<fpage>38</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr25-0272989X10397615">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pogany</surname><given-names>K</given-names></name>
<name><surname>van Valkengoed</surname><given-names>IG</given-names></name>
<name><surname>Prins</surname><given-names>JM</given-names></name>
<etal/>
</person-group>. <article-title>Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN)</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2007</year>;<volume>44</volume>(<issue>4</issue>):<fpage>395</fpage>–<lpage>400</lpage>.</citation>
</ref>
<ref id="bibr26-0272989X10397615">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Powers</surname><given-names>AE</given-names></name>
<name><surname>Marden</surname><given-names>SF</given-names></name>
<name><surname>McConnell</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Effect of long-	cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection</article-title>. <source>AIDS</source>. <year>2006</year>;<volume>20</volume>(<issue>6</issue>):<fpage>837</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr27-0272989X10397615">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruiz</surname><given-names>L</given-names></name>
<name><surname>Paredes</surname><given-names>R</given-names></name>
<name><surname>Gomez</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients</article-title>. <source>AIDS</source>. <year>2007</year>;<volume>21</volume>(<issue>2</issue>):<fpage>169</fpage>–<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr28-0272989X10397615">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Skiest</surname><given-names>DJ</given-names></name>
<name><surname>Krambrink</surname><given-names>A</given-names></name>
<name><surname>Su</surname><given-names>Z</given-names></name>
<name><surname>Robertson</surname><given-names>KR</given-names></name>
<name><surname>Margolis</surname><given-names>DM</given-names></name>
</person-group>. <article-title>Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2008</year>;<volume>49</volume>(<issue>4</issue>):<fpage>377</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr29-0272989X10397615">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tuldra</surname><given-names>A</given-names></name>
<name><surname>Fumaz</surname><given-names>CR</given-names></name>
<name><surname>Ferrer</surname><given-names>MJ</given-names></name>
<etal/>
</person-group>. <article-title>Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads</article-title>. <source>AIDS</source>. <year>2001</year>;<volume>15</volume>(<issue>14</issue>):<fpage>1904</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr30-0272989X10397615">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Joyce</surname><given-names>VR</given-names></name>
<name><surname>Barnett</surname><given-names>PG</given-names></name>
<name><surname>Bayoumi</surname><given-names>AM</given-names></name>
<etal/>
</person-group>. <article-title>Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2009</year>;<volume>50</volume>(<issue>1</issue>):<fpage>27</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr31-0272989X10397615">
<label>31.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Singer</surname><given-names>JD</given-names></name>
<name><surname>Willet</surname><given-names>JB</given-names></name>
</person-group>. <source>Applied Longitudinal Data Analysis</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>; <year>2003</year>.</citation>
</ref>
<ref id="bibr32-0272989X10397615">
<label>32.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Fairclough</surname><given-names>DL</given-names></name>
</person-group>. <source>Design and Analysis of Quality of Life Studies in Clinical Trials</source>. <publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>Chapman &amp; Hall/CRC</publisher-name>; <year>2002</year>.</citation>
</ref>
<ref id="bibr33-0272989X10397615">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anis</surname><given-names>AH</given-names></name>
<name><surname>Nosyk</surname><given-names>B</given-names></name>
<name><surname>Sun</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-	defining events and non-AIDS serious adverse events</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2009</year>;<volume>51</volume>(<issue>5</issue>):<fpage>631</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr34-0272989X10397615">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Protopopescu</surname><given-names>C</given-names></name>
<name><surname>Marcellin</surname><given-names>F</given-names></name>
<name><surname>Spire</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8)</article-title>. <source>Qual Life Res</source>. <year>2007</year>;<volume>16</volume>(<issue>4</issue>):<fpage>577</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr35-0272989X10397615">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wu</surname><given-names>AW</given-names></name>
<name><surname>Jacobson</surname><given-names>KL</given-names></name>
<name><surname>Frick</surname><given-names>KD</given-names></name>
<etal/>
</person-group>. <article-title>Validity and responsiveness of the Euroqol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial</article-title>. <source>Qual Life Res</source>. <year>2002</year>;<volume>11</volume>(<issue>3</issue>):<fpage>273</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr36-0272989X10397615">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Revicki</surname><given-names>DA</given-names></name>
<name><surname>Moyle</surname><given-names>G</given-names></name>
<name><surname>Stellbrink</surname><given-names>HJ</given-names></name>
<name><surname>Barker</surname><given-names>C</given-names></name>
</person-group>. <article-title>Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-	zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group</article-title>. <source>AIDS</source>. <year>1999</year>;<volume>13</volume>(<issue>7</issue>):<fpage>851</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr37-0272989X10397615">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>C</given-names></name>
<name><surname>Revicki</surname><given-names>DA</given-names></name>
<name><surname>Nabulsi</surname><given-names>A</given-names></name>
<name><surname>Sarocco</surname><given-names>PW</given-names></name>
<name><surname>Jiang</surname><given-names>P</given-names></name>
</person-group>. <article-title>A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group</article-title>. <source>AIDS</source>. <year>1998</year>;<volume>12</volume>(<issue>12</issue>):<fpage>1495</fpage>–<lpage>502</lpage>.</citation>
</ref>
<ref id="bibr38-0272989X10397615">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>CJ</given-names></name>
<name><surname>Clumeck</surname><given-names>N</given-names></name>
<name><surname>Molina</surname><given-names>JM</given-names></name>
<etal/>
</person-group>. <article-title>Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2004</year>;<volume>37</volume>(<issue>1</issue>):<fpage>1140</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr39-0272989X10397615">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huang</surname><given-names>IC</given-names></name>
<name><surname>Wu</surname><given-names>AW</given-names></name>
<name><surname>Finnern</surname><given-names>HW</given-names></name>
<name><surname>Thijs</surname><given-names>H</given-names></name>
<name><surname>Gathe</surname><given-names>JC</given-names></name>
<name><surname>Fairclough</surname><given-names>DL</given-names></name>
</person-group>. <article-title>Health-related quality of life and tolerability in treatment-experienced HIV-1-infected patients on tipranavir versus comparator regimens</article-title>. <source>Antivir Ther</source>. <year>2008</year>;<volume>13</volume>(<issue>1</issue>):<fpage>15</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr40-0272989X10397615">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Preau</surname><given-names>M</given-names></name>
<name><surname>Leport</surname><given-names>C</given-names></name>
<name><surname>Salmon-Ceron</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment</article-title>. <source>AIDS Care</source>. <year>2004</year>;<volume>16</volume>(<issue>5</issue>):<fpage>649</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr41-0272989X10397615">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Braithwaite</surname><given-names>RS</given-names></name>
<name><surname>Goulet</surname><given-names>J</given-names></name>
<name><surname>Kudel</surname><given-names>I</given-names></name>
<name><surname>Tsevat</surname><given-names>J</given-names></name>
<name><surname>Justice</surname><given-names>AC</given-names></name>
</person-group>. <article-title>Quantifying the decrement in utility from perceived side effects of combination antiretroviral therapies in patients with HIV</article-title>. <source>Value Health</source>. <year>2008</year>;<volume>11</volume>(<issue>5</issue>):<fpage>975</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr42-0272989X10397615">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsevat</surname><given-names>J</given-names></name>
<name><surname>Sherman</surname><given-names>SN</given-names></name>
<name><surname>McElwee</surname><given-names>JA</given-names></name>
<etal/>
</person-group>. <article-title>The will to live among HIV-infected patients</article-title>. <source>Ann Intern Med</source>. <year>1999</year>;<volume>131</volume>(<issue>3</issue>):<fpage>194</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr43-0272989X10397615">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coleman</surname><given-names>CL</given-names></name>
</person-group>. <article-title>Spirituality and sexual orientation: relationship to mental well-being and functional health status</article-title>. <source>J Adv Nurs</source>. <year>2003</year>;<volume>43</volume>(<issue>5</issue>):<fpage>457</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr44-0272989X10397615">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cotton</surname><given-names>S</given-names></name>
<name><surname>Puchalski</surname><given-names>CM</given-names></name>
<name><surname>Sherman</surname><given-names>SN</given-names></name>
<etal/>
</person-group>. <article-title>Spirituality and religion in patients with HIV/AIDS</article-title>. <source>J Gen Intern Med</source>. <year>2006</year>;<volume>21</volume> <issue>Suppl 5</issue>:<fpage>S5</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr45-0272989X10397615">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cotton</surname><given-names>S</given-names></name>
<name><surname>Tsevat</surname><given-names>J</given-names></name>
<name><surname>Szaflarski</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Changes in religiousness and spirituality attributed to HIV/AIDS: are there sex and race differences?</article-title> <source>J Gen Intern Med</source>. <year>2006</year>;<volume>21</volume> <issue>Suppl 5</issue>:<fpage>S14</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr46-0272989X10397615">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mrus</surname><given-names>JM</given-names></name>
<name><surname>Sherman</surname><given-names>KE</given-names></name>
<name><surname>Leonard</surname><given-names>AC</given-names></name>
<name><surname>Sherman</surname><given-names>SN</given-names></name>
<name><surname>Mandell</surname><given-names>KL</given-names></name>
<name><surname>Tsevat</surname><given-names>J</given-names></name>
</person-group>. <article-title>Health values of patients coinfected with HIV/hepatitis C: are two viruses worse than one?</article-title> <source>Med Care</source>. <year>2006</year>;<volume>44</volume>(<issue>2</issue>):<fpage>158</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr47-0272989X10397615">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vidrine</surname><given-names>DJ</given-names></name>
<name><surname>Amick</surname><given-names>BC</given-names><suffix>III</suffix></name>
<name><surname>Gritz</surname><given-names>ER</given-names></name>
<name><surname>Arduino</surname><given-names>RC</given-names></name>
</person-group>. <article-title>Functional status and overall quality of life in a multiethnic HIV-positive population</article-title>. <source>AIDS Patient Care STDS</source>. <year>2003</year>;<volume>17</volume>(<issue>4</issue>):<fpage>187</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr48-0272989X10397615">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Feeny</surname><given-names>D</given-names></name>
<name><surname>Blanchard</surname><given-names>C</given-names></name>
<name><surname>Mahon</surname><given-names>JL</given-names></name>
<etal/>
</person-group>. <article-title>Comparing community-	preference-based and direct standard gamble utility scores: evidence from elective total hip arthroplasty</article-title>. <source>Int J Technol Assess Health Care</source>. <year>2003</year>;<volume>19</volume>(<issue>2</issue>):<fpage>362</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr49-0272989X10397615">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Feeny</surname><given-names>D</given-names></name>
<name><surname>Furlong</surname><given-names>W</given-names></name>
<name><surname>Saigal</surname><given-names>S</given-names></name>
<name><surname>Sun</surname><given-names>J</given-names></name>
</person-group>. <article-title>Comparing directly measured standard gamble scores to HUI2 and HUI3 utility scores: group- and individual-level comparisons</article-title>. <source>Soc Sci Med</source>. <year>2004</year>;<volume>58</volume>(<issue>4</issue>):<fpage>799</fpage>–<lpage>809</lpage>.</citation>
</ref>
<ref id="bibr50-0272989X10397615">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rashidi</surname><given-names>AA</given-names></name>
<name><surname>Anis</surname><given-names>AH</given-names></name>
<name><surname>Marra</surname><given-names>CA</given-names></name>
</person-group>. <article-title>Do visual analogue scale (VAS) derived standard gamble (SG) utilities agree with Health Utilities Index utilities? A comparison of patient and community preferences for health status in rheumatoid arthritis patients</article-title>. <source>Health Qual Life Outcomes</source>. <year>2006</year>;<volume>4</volume>:<fpage>25</fpage>.</citation>
</ref>
</ref-list>
</back>
</article>